Tissue Regenix Group Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Jay LeCoque
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | less than a year |
| Board average tenure | 9.3yrs |
Recent management updates
Recent updates
Investors Don't See Light At End Of Tissue Regenix Group plc's (LON:TRX) Tunnel And Push Stock Down 28%
Sep 30
Tissue Regenix Group plc (LON:TRX) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough
Jul 18Why Investors Shouldn't Be Surprised By Tissue Regenix Group plc's (LON:TRX) 28% Share Price Plunge
Mar 08Does Tissue Regenix Group (LON:TRX) Have A Healthy Balance Sheet?
Nov 02Tissue Regenix Group plc's (LON:TRX) Share Price Is Matching Sentiment Around Its Revenues
Jun 01Tissue Regenix Group plc's (LON:TRX) Shares Bounce 25% But Its Business Still Trails The Industry
Feb 25Is Tissue Regenix Group (LON:TRX) A Risky Investment?
Jun 10Tissue Regenix Group plc (LON:TRX): Are Analysts Optimistic?
Apr 02Tissue Regenix Group plc (LON:TRX): Are Analysts Optimistic?
Nov 18
CEO
Jay LeCoque (63 yo)
Mr. Jay Charles LeCoque is Director at Tissue Regenix Group plc since September 04, 2025 and also serves as its Executive Chairman of the Board since September 08, 2025 and serves as Acting Chief Executive...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Acting CEO & Executive Chairman | less than a year | no data | no data | |
| CFO, Company Secretary & Director | 6yrs | no data | 0.16% £ 8.2k | |
| Interim CFO | less than a year | no data | no data | |
| Technical & Operations Director - UK | no data | no data | no data |
Experienced Management: TRX's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Acting CEO & Executive Chairman | less than a year | no data | no data | |
| CFO, Company Secretary & Director | less than a year | no data | 0.16% £ 8.2k | |
| Independent Non-Executive Director | 4.8yrs | US$45.00k | 0.22% £ 11.6k | |
| Member of Orthopedic Clinical Advisory Board for US | 9.3yrs | no data | no data | |
| Independent Non-Executive Director | 9.4yrs | US$38.00k | 0.023% £ 1.2k | |
| Member of Orthopedic Clinical Advisory Board for US | 9.3yrs | no data | no data | |
| Member of Orthopedic Clinical Advisory Board for US | 9.3yrs | no data | no data | |
| Member of Orthopedic Clinical Advisory Board for US | 9.3yrs | no data | no data | |
| Member of Orthopedic Clinical Advisory Board for US | 9.3yrs | no data | no data |
Experienced Board: TRX's board of directors are considered experienced (9.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/16 12:27 |
| End of Day Share Price | 2025/10/22 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tissue Regenix Group plc is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christopher Donnellan | Cavendish |
| Nyeok Lee | Jefferies LLC |
| Paul Cuddon | Peel Hunt LLP |